SANUWAVE Health, Inc. (SNWV) - Comprehensive Stock Profile
Key Finding: SANUWAVE Health, Inc. (SNWV) is a medical device company focused on non-invasive ultrasound wound care (UltraMIST) that achieved record revenues in 2025 with strong growth but has experienced significant stock volatility, including a recent guidance cut and price swings from a 52-week high near $46.59 to lows around $7.53.020
Company Overview
Core Business: SANUWAVE Health, Inc. operates as a medical device company specializing in the commercialization of regenerative medicine technologies using noninvasive ultrasound or shockwaves to promote tissue repair and regeneration, primarily in wound care. Its flagship product is the FDA-cleared UltraMIST system, which delivers non-thermal ultrasound via a saline mist for pain-free treatment of acute and chronic wounds.
- Headquarters: Eden Prairie, Minnesota
- Employees: Approximately 55
- CEO: Morgan C. Frank
- Sector/Industry: Healthcare / Medical Devices
- Website: sanuwave.com
- Primary Market: United States (majority of revenue), with some international presence
Interpretation: The company positions itself in the advanced wound care market, leveraging patented directed-energy technology to address healing at the cellular level, potentially offering advantages in speed, pain reduction, and process efficiency for providers and patients.
Company History
- Founded: 2004 (originally focused on shockwave and ultrasound technologies for regenerative applications).
- Developed and commercialized products like UltraMIST for wound healing, with applications in musculoskeletal, vascular, and other areas.
- Key Milestone: Uplisted to Nasdaq Global Market; trading commenced March 7, 2025, under ticker SNWV (previously OTC or other venues).
- Relocated headquarters to Eden Prairie, MN in 2022.
- Completed SPAC-related merger activities around 2023 to support growth and listing.
Data Limitation: Detailed pre-2025 financial or operational history is limited in public sources; much early development focused on R&D and regulatory clearances.
Recent News (2025-2026)
- Q1 2026 Results: Revenue of $9.6–9.7 million (up ~3-4% YoY), highest Q1 in company history; gross margins ~77%; narrowed guidance range.5
- Q2 2026 Guidance Update (June 2026): Reduced to $8.5–9.5 million from prior $11.1–11.6 million outlook, citing market pressures.29
- FY 2025 Highlights: Record full-year revenue ~$44.1–44.4 million (up ~35-36% YoY); Q4 revenue $13.3–13.4 million (up 29-30% YoY).17
- Other Developments: Addition of UltraMIST to major GPO contracts (e.g., Healogics); participation in investor conferences; analyst coverage with Buy ratings (e.g., Roth Capital target lowered to $47 from $53 in March 2026).35
- Stockholder Actions: Approved governance matters in mid-2026.
Uncertainty: Recent guidance reductions introduce execution risk amid reimbursement changes in wound care (e.g., skin substitutes); future performance depends on commercial expansion and market adaptation.
Stock Performance
As of latest data (around July 8-9, 2026): Price fluctuated significantly; recent closes near $10.10–$12.10 with daily moves of ±6-20%. Market cap ~$87–107 million. 52-week range: $7.53 – $46.59. Volume often elevated on news.
Key Performance Metrics (approximate, trailing periods as of early July 2026)
| Period | SNWV Return | S&P 500 Return (approx.) |
|---|
| YTD | +66% | +9% |
| 1-Year | +71% | +20% |
| 3-Year | +1% | +70% |
| 5-Year | +1% (or negative in some views) | +73% |
Interpretation: Strong longer-term outperformance from very low bases in prior years, but high volatility and recent pullback from 2025-2026 highs suggest sensitivity to earnings, guidance, and sector reimbursement news. Beta ~1.42 indicates higher volatility than the market.
Financial Snapshot (TTM approx. from sources)
| Metric | Value |
|---|
| Revenue (TTM) | ~$44.3M |
| Net Income (TTM) | ~$16.5M |
| EPS (TTM) | ~$0.90 |
| Profit Margin | ~37% |
| Market Cap | ~$87–107M |
| P/E (TTM) | ~11 |
Links for More Information
Data Limitations & Assumptions: All information is compiled from publicly available web sources as of July 2026 and reflects data available at the time of retrieval (e.g., closing prices, preliminary revenues subject to final audit). Stock prices are highly volatile and change rapidly; historical returns do not predict future results. Revenue figures for recent quarters are often preliminary ranges. No investment advice is provided; consult professional advisors and verify latest filings (e.g., SEC, earnings transcripts). Assumptions include standard fiscal year alignment and focus on English-language sources.